The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens
Perindopril erbumine , a new long‐acting , non‐sulfhydryl‐containing angiotensin converting enzyme inhibitor , was evaluated in 289 patients with hypertension in a 16‐week , double‐blind , placebo‐controlled dose‐ranging study . After 4 weeks of single‐blind placebo treatment , patients with supine diastolic arterial pressures from 95 to 114 mm Hg were r and omized to receive placebo , 4 mg perindopril once daily , or 2 mg perindopril twice daily . The daily dose of perindopril was increased by 4 mg every 4 weeks to a maximum of 16 mg per day . Mean decreases in systolic and diastolic arterial pressure were greater with perindopril than with placebo ( p < 0.05 ) . The dose‐response curve flattened after 8 mg per day , and there was no difference in arterial pressure reduction or in the percentage of responders between once‐ and twice‐daily administration of perindopril . Adverse reactions with perindopril were generally mild and , with the exception of cough , were similar with placebo . The findings of this study indicate that perindopril is effective , well tolerated , and suitable for once‐daily administration for the treatment of hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .